Regeneron Pharmaceuticals
(NASDAQ) REGN
Regeneron Pharmaceuticals Financials at a Glance
Market Cap
$80.23B
Revenue (TTM)
$14.34B
Net Income (TTM)
$4.50B
EPS (TTM)
$41.56
P/E Ratio
18.26
Dividend
$3.58
Beta (Volatility)
0.61 (Low)
Dividend
$3.58
Beta (Volatility)
0.61 (Low)
Price
$745.07
Volume
6,714
Open
$754.81
Price
$745.07
Volume
6,714
Open
$754.81
Previous Close
$759.05
Daily Range
$734.97 - $757.41
52-Week Range
$476.49 - $821.11
Dividend
$3.58
Beta (Volatility)
0.61 (Low)
Price
$745.07
Volume
6,714
Open
$754.81
Previous Close
$759.05
Daily Range
$734.97 - $757.41
52-Week Range
$476.49 - $821.11
REGN News
REGN: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Regeneron Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
15,410
CEO
Leonard S. Schleifer, MD, PhD
Website
www.regeneron.comHeadquarters
Tarrytown, NY 10591-6707, US
REGN Financials
Key Financial Metrics (TTM)
Gross Margin
85%
Operating Margin
25%
Net Income Margin
31%
Return on Equity
15%
Return on Capital
10%
Return on Assets
11%
Earnings Yield
5.48%
Dividend Yield
0.00%
Payout Ratio
8.22%
Stock Overview
Market Cap
$80.23B
Shares Outstanding
105.70M
Volume
6.71K
Short Interest
0.00%
Avg. Volume
773.92K
Financials (TTM)
Gross Profit
$12.24B
Operating Income
$3.58B
EBITDA
$5.82B
Operating Cash Flow
$4.98B
Capital Expenditure
$898.40M
Free Cash Flow
$4.08B
Cash & ST Invst.
$8.61B
Total Debt
$2.71B
Regeneron Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$3.88B
+2.5%
Gross Profit
$3.30B
+2.4%
Gross Margin
84.95%
N/A
Market Cap
$80.23B
N/A
Market Cap/Employee
$5.29M
N/A
Employees
15,158
N/A
Net Income
$844.60M
-8.0%
EBITDA
$1.20B
+9.7%
Quarterly Fundamentals
Net Cash
$5.90B
-6.5%
Accounts Receivable
$5.74B
-7.6%
Inventory
$3.20B
+3.7%
Long Term Debt
$2.71B
+0.1%
Short Term Debt
$0.00
N/A
Return on Assets
11.11%
N/A
Return on Invested Capital
9.89%
N/A
Free Cash Flow
$922.00M
-7.4%
Operating Cash Flow
$1.17B
-7.3%